Vaccinex Profit Margin

The latest profit margin for VCNX is -3100.5% as of December 2024. That compares with -10992.93% in the prior-year period — up 71.8% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Vaccinex's historical trend and sector peers before judging valuation or financial health.

Over the past year, VCNX's profit margin moved from -10992.93% to -3100.5% — a 71.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vaccinex's valuation or profitability profile.

Against Healthcare companies, VCNX currently prints -3100.5% for profit margin, while the sector average sits near 15.29%. That is roughly 20374.1% below the sector mean. Large gaps often invite a closer look at Vaccinex's growth, margins, and balance sheet.

Profit Margin shows how effectively Vaccinex converts resources into returns. At -3100.5%, VCNX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -10992.93% in the prior-year period — up 71.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting VCNX's profit margin (-3100.5%), review year-over-year change from -10992.93%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.